Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.41 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RARB | P10826 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10120811 | 0.97 | SPHK1 (0.44) | LMNASPHK1SPHK2USP2HTT | |
| SCHEMBL25940118 | 0.97 | SPHK1 (0.44) | LMNASPHK1SPHK2USP2HTT | |
| SCHEMBL10119363 | 0.97 | SPHK1 (0.44) | LMNASPHK1SPHK2USP2HTT | |
| SCHEMBL7866199 | 0.97 | SPHK1 (0.44) | LMNASPHK1SPHK2USP2HTT | |
| SCHEMBL25565580 | 0.93 | SPHK1 (0.41) | LMNASPHK1SPHK2USP2HTT | |
| SCHEMBL10498220 | 0.93 | SPHK1 (0.41) | LMNASPHK1SPHK2USP2HTT | |
| SCHEMBL26719977 | 0.92 | SPHK1 (0.37) | LMNASPHK1SPHK2USP2HTT | |
| SCHEMBL12031279 | 0.92 | LMNA (0.39) | LMNASPHK1SPHK2USP2HTT | |
| SCHEMBL11858528 | 0.89 | SPHK1 (0.42) | SPHK1SPHK2USP2HTTCYP3A4 | |
| SCHEMBL16248567 | 0.87 | LMNA (0.36) | LMNASPHK1SPHK2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238435-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240216522-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA | DYNE THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240209119-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | DYNE THERAPEUTICS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240066140-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240016952-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | US | disclosed |
| US-11839660-B2 | Anti-transferrin receptor antibody and uses thereof | DYNE THERAPEUTICS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230357270-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF RED BLOOD DISORDERS AND INFLAMMATORY DISEASES | SANOFI (FR) | 2023-11-09 | — | — | US | disclosed |
| US-20230346967-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | DYNE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | US | disclosed |
| US-20230330562-A1 | METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES | DYNE THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230321264-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | DYNE THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20080167311-A1 | Prostaglandin Prodrugs | ALLERGAN, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20080119539-A1 | THERAPEUTIC AMIDES | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080119538-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-05-22 | — | — | US | disclosed |
| US-20080058397-A1 | 5-(3-(3-(4-hexanoylphenyl)-2,5-dioxoimidazolidin-4-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agent; post-sergical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | OLD DAVID W | 2008-03-06 | — | — | US | disclosed |
| US-20080058387-A1 | 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | ALLERGAN, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080051374-A1 | Therapeutic Amides and related Compounds | ALLERGAN, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | ALLERGAN, INC. | 2008-02-21 | — | — | US | disclosed |
| US-20080039505-A1 | THERAPEUTIC LACTAMS | ALLERGAN, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080027108-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | ALLERGAN, INC. | 2008-01-31 | — | — | US | disclosed |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | ALLERGAN, INC. | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (20 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016952-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | MUSK, MYOF, MYLK2 | LMNA 373/4885SPHK1 1685/4885SPHK2 1476/4885 |
| US-20080051374-A1 | Therapeutic Amides and related Compounds | GOT2, ACER2, GOT1 | LMNA 3216/4885SPHK1 2288/4885SPHK2 1593/4885 |
| US-11839660-B2 | Anti-transferrin receptor antibody and uses thereof | TFRC, FTH1, FOLR1 | LMNA 4703/4885SPHK1 3870/4885SPHK2 3920/4885 |
| US-20080027108-A1 | THERAPEUTIC SUBSTITUTED LACTAMS | SI, GGPS1, B3GAT3 | LMNA 3131/4885SPHK1 2118/4885SPHK2 2610/4885 |
| US-20080119539-A1 | THERAPEUTIC AMIDES | GOT2, GOT1, ARG2 | LMNA 3086/4885SPHK1 2821/4885SPHK2 2218/4885 |
| US-20230321264-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | MUSK, MYOF, UTRN | LMNA 1506/4885SPHK1 3891/4885SPHK2 3709/4885 |
| US-20080039505-A1 | THERAPEUTIC LACTAMS | CLPP, NOTUM, PEPD | LMNA 3171/4885SPHK1 3821/4885SPHK2 4094/4885 |
| US-20230357270-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF RED BLOOD DISORDERS AND INFLAMMATORY DISEASES | NFE2L2, KEAP1, NFE2 | LMNA 2526/4885SPHK1 1900/4885SPHK2 1394/4885 |
| US-20080167311-A1 | Prostaglandin Prodrugs | PTGES, PTGIS, PTGER1 | LMNA 1925/4885SPHK1 531/4885SPHK2 422/4885 |
| US-20240216522-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FRIEDREICH'S ATAXIA | MUSK, ATXN2, ATXN10 | LMNA 464/4885SPHK1 3677/4885SPHK2 3122/4885 |
| US-20080045576-A1 | THERAPEUTIC N-ARYL OR N-HETEROARYL PYRAZOLIDINE AND PYRAZOLIDINONE DERIVATIVES | GOT2, GOT1, NME4 | LMNA 935/4885SPHK1 960/4885SPHK2 642/4885 |
| US-20240066140-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY | MUSK, MYOF, UTRN | LMNA 1506/4885SPHK1 3891/4885SPHK2 3709/4885 |
| US-20080058397-A1 | 5-(3-(3-(4-hexanoylphenyl)-2,5-dioxoimidazolidin-4-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agent; post-sergical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | PTGIS, PTGIR, PTGS1 | LMNA 983/4885SPHK1 435/4885SPHK2 266/4885 |
| US-20080058387-A1 | 5-(3-(3-(4-(1-hydroxyhexyl)phenyl)-4-oxo-thiazolidin-2-yl)propyl)thiophene-2-carboxylic acid; prostaglandin agonist; ocular hypotensive agents; post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts | PTGIS, PTGIR, PTGS1 | LMNA 1226/4885SPHK1 1072/4885SPHK2 845/4885 |
| US-20240209119-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | UTRN, MUSK, SMN1; SMN2 | LMNA 359/4885SPHK1 4017/4885SPHK2 3846/4885 |
| US-20230330562-A1 | METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES | PHAX, RAB5IF, CD2BP2 | LMNA 2858/4885SPHK1 4832/4885SPHK2 4773/4885 |
| US-20080119538-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, GOT1 | LMNA 1806/4885SPHK1 2531/4885SPHK2 2064/4885 |
| US-20240238435-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY | MUSK, MYOF, MYLK2 | LMNA 373/4885SPHK1 1685/4885SPHK2 1476/4885 |
| US-20080015231-A1 | THERAPEUTIC COMPOUNDS | GOT2, ANXA5, COXFA4L2 | LMNA 2115/4885SPHK1 1800/4885SPHK2 1461/4885 |
| US-20230346967-A1 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | UTRN, MUSK, MYOF | LMNA 372/4885SPHK1 3946/4885SPHK2 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.